Key Takeaways
- Multiple gene therapies for wet AMD show promising durability data, but face adoption hurdles around delivery methods and implementation.
- Novel combination therapies could see faster uptake by working within existing treatment paradigms while potentially offering superior efficacy
As biosimilars flood into the wet age-related macular degeneration (AMD) market, they are reshaping the competitive landscape that was long dominated by anti-vascular endothelial growth factor (VEGF) treatments like
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?